Immune checkpoint inhibitors are a revolutionary cancer treatment, demonstrating remarkable efficacy and manageable toxicity with dramatic clinical results, particularly in patients with melanoma and lung cancer [1, 2] . Several case studies involving patients affected by cutaneous melanoma, lung cancer, lymphoma and other solid tumours undergoing or candidates for immunotherapy and 18 F-fluorodeoxyglucose ( 18 F-FDG) positron emission tomography/computed tomography (PET/CT) have been published [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] ; however, many inconsistencies in the treatment response assessment by PET/CT in patients undergoing immunotherapy can be found in the literature and in clinical practice. The main question is "when and how should 18 F-FDG PET/CT be performed during immunotherapy?"
First, some papers have discussed the usefulness of 18 F-FDG PET/CT in predicting the response to immunotherapy. In the study by Grizzi et al. [8] , in patients affected by lung cancer, a low maximum standardised uptake value (SUVmax) in the primary tumour was associated with a fast disease progression during immunotherapy. Moreover, Evangelista et al. [13] found that a widespread lung disease with a high tumoural burden (evaluating by whole-body SUVmax or whole-body SUVmean) was correlated with the failure of immunotherapy, especially in female patients. No data about the prediction of response to immunotherapy and 18 F-FDG PET/CT are available in other solid tumours (i.e. breast cancer, mesothelioma, or others), representing an important point of view.
Second, the timing between immunotherapy administration and 18 F-FDG PET/CT scanning is variable (at least 10 days or 15 days or 21 days) since no recommendation is given in the published reports. Moreover, the ideal timing between 18 F-FDG PET/CT scanning and immunotherapy cycles, both interim and the end, is unclear. By analysing the published literature, heterogeneous conclusions can been drawn about the interval period between immunotherapy administration and the evaluation of response to therapy by 18 F-FDG PET/CT. Cho et al. [3] prospectively enrolled 20 patients with cutaneous melanoma who underwent 18 F-FDG PET/CT at baseline, after 21 days and after 4 weeks from the administration of immunotherapy, showing the potential of 18 F-FDG PET/CT combined with anatomical data to predict early the response to therapy. In the FIR trial, 18 F-FDG PET/CT was performed prior to treatment and 6 weeks after immunotherapy [12] , reporting a higher objective response rate in patients with metabolic response by European Organisation for Research and Treatment of Cancer (EORTC) criteria than in metabolic non-responders. Probably, the three scan time-points are necessary to evaluate the effective response to immunotherapy, at baseline, after 2 weeks and 6 weeks to minimise false-positive findings in case of pseudo-progression.
Third, different criteria have now been tested for the evaluation of response to immunotherapy by 18 F-FDG PET/CT, although none has been validated and identified as a standard. Table 1 reports the main proposed criteria and their characteristics [3, 4, 11, 14] .
Fourth, clinical assessment and radiological images are now considered the standard for the evaluation of response to immunotherapy. However, some limitations are associated with both, particularly in patients with no response to immunotherapy. Neither clinical nor radiological assessment can distinguish a real progression from pseudo-progression, especially in case of the appearance of immune-related side 1 3 effects. Two papers have recently been published on the utility of 18 F-FDG PET/CT for the evaluation of response to immunotherapy in patients with a suspected progressive disease in clinical evaluation or radiological imaging [5, 10] . In both cases, 18 F-FDG PET/CT seems able to predict the response to immunotherapy, with a clear effect on prognosis.
In our opinion, an effort should be made to define the role of 18 F-FDG PET/CT in the evaluation of response to immunotherapy. Metabolic imaging would be appropriate to (1) select patients who will benefit from immunotherapy; (2) discriminate between patients with a real progression of disease during immunotherapy, especially in the case of doubtful or indeterminate morphological imaging; (3) improve the definition of a clinical benefit; and (4) stratify the prognosis of patients who undergo long-term treatment with immunotherapy. However, multicentre prospective clinical trials should be appropriately drawn. Finally, although few and discordant findings are available about the prediction of response to immunotherapy in patients who will develop immune-related adverse events, the role of 18 F-FDG PET/ CT should be addressed and further evaluated.
To obtain a national overview of the abovementioned matters of discussion, on the behalf of the Italian Association of Nuclear Medicine (AIMN), we have developed an eight-question online survey. However, an international effort should be made for providing definitive solutions to these uncertainties.
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